MAPT and Alzheimer disease: In addition to its impact on Aβ, gantenerumab has effects on multiple biomarkers of AD pathology and neurodegeneration in clinical trials, including dose- and time-dependent reductions in cerebrospinal fluid (CSF) levels of total tau (t-tau), phosphorylated tau (p-tau) reduction, decreases in the synaptic biomarker neurogranin [13, 14], and neurofilament light chain (NfL) reduction [14], which provide evidence supporting gantenerumab’s impact in several biological aspects of AD pathophysiology.